Nadia Yaqub, MD
Endocrinology, Diabetes & Metabolism · Fairfield, OHNPI 1891750287
Payments from drug & device makers
Across 220 payments — averaging $22.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$623
- Medtronic$429
- Amgen$348
- Insulet Corporation$315
- Lilly USA, LLC$309
- Boehringer Ingelheim$275
- plus $3K from 31 others
What the payments were for
- Food & beverage$4,71897%
- Education$1563%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 55 | $623 |
| Medtronic(2 entities) | 14 | $429 |
| Amgen(2 entities) | 11 | $348 |
| Insulet Corporation | 13 | $315 |
| Lilly USA, LLC | 20 | $309 |
| Boehringer Ingelheim | 5 | $275 |
| Sanofi-aventis U.S. LLC | 16 | $241 |
| Amarin Pharma, Inc. | 7 | $231 |
| Neurocrine Biosciences, Inc. | 5 | $222 |
| Abbott | 4 | $203 |
| AstraZeneca | 6 | $191 |
| Tandem Diabetes Care, Inc. | 7 | $167 |
| Mannkind Corporation | 6 | $161 |
| Bayer | 3 | $141 |
| Ascendis Pharma Endocrinology Inc | 2 | $105 |
| Merck | 7 | $97 |
| Sanofi | 2 | $93 |
| BETA Bionics, Inc. | 4 | $90 |
| Dexcom, Inc. | 5 | $86 |
| Akcea Therapeutics, Inc. | 1 | $72 |
| Xeris Pharmaceuticals, Inc. | 4 | $63 |
| Radius Health, Inc. | 1 | $50 |
| Antares Pharma, Inc. | 3 | $48 |
| Sequel Med Tech, LLC | 2 | $46 |
| Ascensia Diabetes Care US Inc. | 2 | $40 |
| AbbVie | 2 | $30 |
| Shire North American Group Inc | 2 | $27 |
| Johnson & Johnson | 2 | $26 |
| Amneal Pharmaceuticals LLC | 1 | $25 |
| Cequr Corporation | 1 | $21 |
| IBSA Pharma Inc. | 1 | $20 |
| Halozyme Inc | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $18 |
| Acella Pharmaceuticals, LLC | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $11 |
| Vivus LLC | 1 | $8 |
| Lifescan, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FREESTYLE LIBRE 3$149
- Minimed 670G System$139
- CRENESSITY$137
- MINIMED 780G$133
- Vascepa$123
- Omnipod$113
- Tresiba$103
- TEPEZZA$103
- Kerendia$102
How this compares
$4,873 in reported general payments places this provider in the 70th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 513 | $659,101 |
| OzempicSemaglutide | 430 | $590,939 |
| JardianceEmpagliflozin | 350 | $314,184 |
| TrulicityDulaglutide | 112 | $139,242 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 110 | $123,700 |
| SynjardyEmpagliflozin/Metformin Hcl | 126 | $119,414 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 122 | $97,747 |
| Tresiba Flextouch U-100Insulin Degludec | 107 | $79,362 |
| Tresiba Flextouch U-200Insulin Degludec | 47 | $76,983 |
| FarxigaDapagliflozin Propanediol | 58 | $59,136 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 48 | $47,044 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 281 | $43,216 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 55 | $42,606 |
| Novolog FlexpenInsulin Aspart | 131 | $40,908 |
| Humalog Kwikpen U-100Insulin Lispro | 115 | $35,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Baqsimi, Insulin Lispro | $309 | $823,943733 claims |
| Novo NordiskOzempic, Fiasp, Novolog | $623 | $613,129464 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr | $275 | $455,157501 claims |
| MerckJanumet, Janumet Xr, Januvia | $97 | $60,55058 claims |
| AstraZenecaFarxiga | $191 | $59,13658 claims |
| Sanofi-aventis U.S. LLCLantus, Admelog | $241 | $11,47252 claims |
| AbbVieSynthroid | $30 | $8,682161 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $25 | $4,177581 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Fairfield
- Toby BriskinBedford$9.8M
- Charles SmithCanton$5.3M
- Kevin PantaloneCleveland$4M
- Elena ChristofidesColumbus$3.5M
- Arvind KrishnaCanton$3.1M
- Bartolome BurgueraCleveland$3.1M
- Steven IngColumbus$1.9M
- Kathleen DunganColumbus$1.4M
- Kyaw SoeColumbus$1.3M
- John PaesWesterville$671K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.